Abstract 39P
Background
This study aims to investigate the immunohistochemical expression of HIF-1α, GLUT1, and CA IX in patients with invasive ductal breast cancer (IDC) and assess their correlation with the maximum standardized uptake value of the primary tumor (pSUVmax) and other biological parameters. Additionally, the prognostic significance of pSUVmax, HIF-1α, GLUT1, and CA IX in predicting progression-free survival (PFS) will be evaluated.
Methods
A total of 174 female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled in this study. The pSUVmax was compared with clinicopathological parameters, including estrogen receptor (ER), progesterone receptor (PR), HER2 status, axillary lymph node metastasis (LNM), cancer stage, GLUT1, CA IX, and HIF-1α. The prognostic value of pSUVmax, GLUT1, CA IX, and HIF-1α for PFS was analyzed using the Kaplan-Meier method.
Results
The study revealed that pSUVmax was significantly higher in patients with HIF-1α≥2, GLUT1≥5, and CA IX≥3, compared to patients with HIF-1α<2, GLUT1<5, and CA IX<3 (4.9±4.1 vs. 3.9±3.2, P=0.02; 6.1±4.2 vs. 3.5±3.0, P=0.003; 5.9±4.5 vs. 3.8±3.2, P=0.003). Furthermore, patients with disease progression had significantly higher pSUVmax values than those who remained disease-free (6.4±3.5 vs. 4.1±3.6, P=0.0045). Receiver-operating characteristic (ROC) curve analysis identified optimal cutoff values for predicting PFS as pSUVmax of 6.8, GLUT1 of 5, and CA IX of 3, with corresponding sensitivities and specificities. Kaplan-Meier analysis revealed that pSUVmax ≥6.8 (P=0.0004), GLUT1≥5 (P=0.0005), and CA IX≥3 (P<0.0001) were predictive of recurrence.
Conclusions
The study findings indicate that pSUVmax on pretreatment F-18 FDG PET/CT can serve as a reliable surrogate marker for predicting progression in patients with IDC. Increased FDG uptake is associated with higher expression levels of HIF-1α, GLUT1, and CA IX, indicating the presence of glucose metabolism and hypoxia in breast cancer cells. These biomarkers hold promise for improved cancer detection and prognostication in IDC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract